25-OH Vitamin D Medication-Driven Changes: What Drugs Raise or Lower Your Level

Why Medications Change Your 25-OH Vitamin D Reading

A 25-OH vitamin D result does not exist in a vacuum. The number on the lab report reflects synthesis in the liver from cholecalciferol or ergocalciferol, but it can be pushed dramatically up or down by drugs your patient may have been taking for years. Clinicians who ignore the medication list risk misinterpreting a low value as dietary negligence or lack of sun exposure, and may miss an iatrogenic cause entirely.

The Metabolism Pathway Drugs Can Interrupt

Vitamin D arrives at the liver as D3 or D2, then gets hydroxylated by CYP2R1 (and to a lesser degree CYP27A1) to form 25-OH vitamin D. From there, CYP27B1 in the kidney converts it to the active hormone 1,25(OH)2D. Several drug classes interfere at one or more of these steps. Endocrine Society clinical practice guidelines define deficiency as a 25-OH level <20 ng/mL and insufficiency as 20 to 29 ng/mL.

Why the 25-OH Assay Is the Right Test

Clinicians sometimes order 1,25(OH)2D instead, but that is the wrong reflex test in most drug-interaction scenarios. The 1,25(OH)2D form has a half-life of only 4 to 6 hours and is tightly regulated by parathyroid hormone (PTH), so it can appear normal even when 25-OH stores are severely depleted. The 25-OH form has a 2 to 3 week half-life and acts as the best surrogate for total body vitamin D status. NIH Office of Dietary Supplements confirms 25-OH vitamin D as the preferred clinical measure.

Drug Classes That Lower 25-OH Vitamin D

These are the medications most consistently documented to reduce measured 25-OH vitamin D levels. The mechanisms vary, but the clinical result is the same: a patient on one of these drugs needs a lower threshold to trigger supplementation and a shorter interval before re-testing.

Glucocorticoids

Prednisone, dexamethasone, and methylprednisolone are the single most common iatrogenic cause of vitamin D depletion in clinical practice. Glucocorticoids reduce intestinal calcium absorption, suppress CYP27B1 activity, and increase renal calcium wasting. A 2012 systematic review found that patients on long-term oral glucocorticoids had 25-OH vitamin D levels averaging 8 to 10 ng/mL lower than matched controls not on steroids. American College of Rheumatology guidelines specifically call for vitamin D supplementation at 800 to 1,000 IU/day in any patient starting chronic glucocorticoid therapy.

Patients receiving inhaled corticosteroids (fluticasone, budesonide) at high doses show a smaller but measurable effect: one observational study in asthmatic adults found a mean 25-OH reduction of approximately 4 ng/mL compared with inhaler-naive controls.

The practical rule: any patient on more than 5 mg/day prednisone equivalent for more than 3 months warrants baseline 25-OH testing, then re-testing at 3 months after starting supplementation.

Anticonvulsants

Phenytoin, carbamazepine, phenobarbital, and primidone induce hepatic CYP450 enzymes, particularly CYP3A4. This accelerates the catabolism of 25-OH vitamin D to inactive polar metabolites, shortening its effective half-life and steadily eroding stored levels. A meta-analysis published in Epilepsia (2010) found that patients on enzyme-inducing anticonvulsants had mean 25-OH vitamin D levels 13.6 ng/mL lower than non-medicated controls, with frank deficiency (<20 ng/mL) in 48% of the anticonvulsant group.

Newer anticonvulsants, including levetiracetam, lamotrigine, and valproate, show much less CYP induction and correspondingly smaller effects on 25-OH levels. Patients switching from phenytoin to levetiracetam often show a spontaneous 8 to 12 ng/mL rise in 25-OH within 6 months without any supplementation change.

Azole Antifungals

Ketoconazole and fluconazole inhibit CYP27B1, the renal enzyme responsible for converting 25-OH vitamin D to active 1,25(OH)2D. Because less substrate is consumed in conversion, some clinicians expect 25-OH to rise on azoles. In practice, ketoconazole at doses used for Cushing syndrome (400 to 1,200 mg/day) reduces 1,25(OH)2D sharply while 25-OH may remain unchanged or drift slightly lower over time. The net clinical picture is functional vitamin D insufficiency despite a borderline-normal 25-OH reading.

Short-course fluconazole (150 mg single-dose for candida) does not meaningfully alter 25-OH vitamin D levels. The interaction is relevant primarily for patients on prolonged systemic courses exceeding 4 weeks.

Bile Acid Sequestrants and Fat-Absorption Inhibitors

Cholestyramine, colestipol, and orlistat all impair fat-soluble vitamin absorption from the GI tract. Vitamin D3 is packaged into chylomicrons, and any drug that disrupts micellar solubilization or chylomicron assembly will reduce its bioavailability. An FDA drug-interaction summary notes that orlistat reduces absorption of fat-soluble vitamins and advises patients to take multivitamin supplements containing vitamins A, D, E, K, and beta-carotene at least 2 hours before or after the orlistat dose.

Patients on cholestyramine for cholesterol control or bile acid diarrhea may see 25-OH values fall 6 to 15 ng/mL over 12 to 18 months even when diet is unchanged.

HIV Antiretrovirals

Tenofovir disoproxil fumarate (TDF) and ritonavir-boosted protease inhibitors both affect vitamin D metabolism through distinct mechanisms. TDF causes proximal tubular injury that can increase renal phosphate and calcium wasting, secondarily altering PTH and vitamin D homeostasis. Ritonavir inhibits CYP3A4 yet paradoxically accelerates vitamin D catabolism via induction of CYP24A1. A cross-sectional study of 884 HIV-positive adults on antiretroviral therapy found vitamin D deficiency in 69% of participants, with TDF use as an independent predictor (OR 1.8, 95% CI 1.2 to 2.6).

Drug Classes That Raise 25-OH Vitamin D

Not all medication-driven changes go in the direction of depletion. A smaller but clinically important group of drugs and conditions elevates 25-OH vitamin D, sometimes to levels approaching toxicity.

Prescribed Cholecalciferol and Ergocalciferol

This is the most straightforward category: pharmaceutical vitamin D supplements directly raise 25-OH levels. The dose-response relationship is roughly linear at physiological replacement doses, with each additional 100 IU/day of cholecalciferol raising steady-state 25-OH by approximately 1 ng/mL in most adults, though individual variation is wide due to CYP2R1 polymorphisms, baseline body fat, and gut absorption efficiency. A dose-finding study in adults (Heaney et al., AJCN 2003) demonstrated that 100 IU/day of D3 raised serum 25-OH by 1.0 ng/mL (2.5 nmol/L), establishing the foundational conversion factor still used in clinical dosing today.

Ergocalciferol (D2), used in high-dose weekly prescriptions (50,000 IU weekly), raises 25-OH less predictably than D3 at equivalent doses, partly because the binding affinity of 25-OH-D2 for vitamin D binding protein (VDBP) is lower, shortening its half-life.

Thiazide Diuretics

Hydrochlorothiazide and chlorthalidone reduce urinary calcium excretion. Less calcium in urine means suppressed PTH, which in turn reduces conversion of 25-OH to 1,25(OH)2D. The substrate 25-OH therefore accumulates at a slightly higher level. The effect is modest, typically a 3 to 5 ng/mL rise in chronic thiazide users compared with diuretic-naive controls. Clinically, this means a patient already on high-dose cholecalciferol who starts hydrochlorothiazide warrants rechecking 25-OH at 3 months to avoid overshooting into the supraphysiologic range.

Calcium Supplements at High Doses

High oral calcium intake (above 1,500 mg/day from supplements) suppresses PTH, which reduces CYP27B1 activity and slows conversion of 25-OH vitamin D. Less substrate consumed in conversion means 25-OH accumulates. The effect is secondary and modest, but it can confound interpretation in patients taking both high-dose calcium and cholecalciferol simultaneously.

Medications With Indirect or Context-Dependent Effects

GLP-1 Receptor Agonists

Semaglutide, liraglutide, and tirzepatide cause substantial weight loss, and adipose tissue is a major storage depot for fat-soluble vitamins including D3. As fat mass shrinks, stored vitamin D is released into circulation. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% on placebo. Patients losing 15 to 20% of body weight on GLP-1 agonists often show a spontaneous 5 to 10 ng/mL rise in 25-OH within 6 months without any supplement change.

The rise is generally beneficial in patients who started below 30 ng/mL, but it can push borderline-high patients (40 to 50 ng/mL at baseline) above the optimal zone. Re-testing 25-OH at 6 months after GLP-1 initiation is a reasonable practice.

Metformin

Long-term metformin use (more than 4 years at doses above 1,000 mg/day) modestly reduces serum 25-OH vitamin D by approximately 3 to 4 ng/mL, likely through interference with ileal bile acid reabsorption and reduced enterohepatic cycling of vitamin D metabolites. The effect is smaller than the glucocorticoid effect and rarely clinically significant in isolation, but it may compound depletion in a patient who is also elderly, housebound, or on a low-fat diet.

Lithium

Lithium increases PTH secretion and can raise 1,25(OH)2D without changing 25-OH substantially. In a small percentage of patients, frank hyperparathyroidism develops, which drives 1,25(OH)2D high enough to cause hypercalcemia. Interpreting a normal 25-OH result in a lithium-treated patient with hypercalcemia requires checking both PTH and 1,25(OH)2D, not just the 25-OH level.

Optimal and Normal 25-OH Vitamin D Ranges

What the Major Guidelines Say

The Endocrine Society's 2011 practice guideline defines vitamin D deficiency as 25-OH <20 ng/mL and insufficiency as 20 to 29 ng/mL. For bone health in adults, the guideline recommends maintaining levels above 30 ng/mL. The full guideline text states: "We recommend screening for vitamin D deficiency in patients at risk for deficiency... We suggest that all adults who are vitamin D deficient be treated with 50,000 IU of vitamin D2 or vitamin D3 once a week for 8 weeks or its equivalent of 6,000 IU of vitamin D2 or vitamin D3 daily."

For longevity and cancer-risk reduction, several investigators have proposed a higher target. The VITAL trial (N=25,871, median follow-up 5.3 years) found that supplementation with 2,000 IU/day of D3 reduced cancer mortality by 25% compared with placebo (HR 0.75, 95% CI 0.59 to 0.96, P=0.02), though it did not reduce total cancer incidence or major cardiovascular events. VITAL results were published in the NEJM (2019).

Practical Target by Clinical Context

| Clinical Context | Suggested 25-OH Target | |---|---| | General adult, no risk factors | 30 to 50 ng/mL | | Chronic glucocorticoid use | 40 to 60 ng/mL | | Enzyme-inducing anticonvulsants | 40 to 60 ng/mL | | Osteoporosis or fracture risk | 40 to 60 ng/mL | | HIV on antiretrovirals | 40 to 60 ng/mL | | GLP-1-induced weight loss, monitoring | 30 to 60 ng/mL | | Post-bariatric surgery | 60 to 80 ng/mL (malabsorption risk) |

Levels above 100 ng/mL carry hypercalcemia risk, and levels above 150 ng/mL are considered toxic by most guidelines. NIH confirms that 25-OH vitamin D concentrations above 150 ng/mL (375 nmol/L) are associated with toxicity.

How to Retest After a Medication Change

The 2 to 3 week half-life of 25-OH vitamin D means that meaningful re-equilibration takes 6 to 8 weeks after any dose adjustment. Re-testing sooner than 8 weeks risks capturing a non-steady-state result and leads to over-correction. The general monitoring protocol used by the HealthRX clinical team follows three decision points:

1. Baseline: Order 25-OH vitamin D before starting any drug known to lower levels.
2. 8-Week Check: Re-test 8 weeks after initiating supplementation or after a dose change.
3. Steady-State Monitoring: Once the patient is in the target range, re-test every 6 months on any level-altering medication, or annually if clinically stable.

Patients on high-dose supplementation (above 4,000 IU/day) also require a serum calcium check alongside 25-OH to screen for developing hypercalcemia before it becomes symptomatic.

Supplementation Protocols for Drug-Depleted Patients

Replenishing From Below 20 ng/mL

The Endocrine Society's loading protocol calls for 50,000 IU of D3 weekly for 8 weeks (total 400,000 IU), then transition to a maintenance dose of 1,500 to 2,000 IU/day. For patients on enzyme-inducing anticonvulsants or glucocorticoids, maintenance doses often need to be 2 to 3 times higher than standard to compensate for accelerated catabolism or impaired absorption.

One practical approach: after completing the loading course, re-test 25-OH. If the level has not reached 30 ng/mL, repeat the 8-week loading course before dropping to maintenance.

Choosing D3 Over D2

Cholecalciferol (D3) outperforms ergocalciferol (D2) at raising and sustaining 25-OH levels. A randomized comparison (Heaney et al., 2011, JCEM) found that D3 was approximately 87% more potent than D2 in raising and maintaining serum 25-OH vitamin D concentrations. For patients on prescriptions written generically as "vitamin D 50,000 IU weekly," confirm with the pharmacy whether the dispensed product is D2 or D3, as many pharmacies still default to ergocalciferol.

Administration Timing on Fat-Absorption-Impairing Drugs

Patients on orlistat or bile acid sequestrants should take cholecalciferol with the largest fat-containing meal of the day, on the opposite end of the dosing window from the absorption-impairing drug. For cholestyramine, separate the vitamin D dose by at least 4 hours. For orlistat, the FDA label specifies at least 2 hours before or after the orlistat dose.

Monitoring Table: Medication, Effect, and Action

| Medication | Direction | Magnitude | Re-test Interval | Supplementation Adjustment | |---|---|---|---|---| | Prednisone >5 mg/day | Lower | 8 to 10 ng/mL | Every 6 months | Add 1,500 to 2,000 IU/day minimum | | Phenytoin / carbamazepine | Lower | 10 to 14 ng/mL | Every 6 months | 2,000 to 4,000 IU/day; may need more | | Orlistat | Lower | 4 to 8 ng/mL | Annually | Separate timing; add 1,000 IU/day | | Cholestyramine | Lower | 6 to 15 ng/mL | Every 6 months | Separate timing; add 1,000 to 2,000 IU/day | | TDF-based ART | Lower | Variable | Every 6 months | 2,000 IU/day; check calcium | | Cholecalciferol D3 | Higher | 1 ng/mL per 100 IU/day | 8 weeks after dose change | Titrate to target | | Hydrochlorothiazide | Higher (modest) | 3 to 5 ng/mL | Annually | Reduce supplement if above 60 ng/mL | | GLP-1 agonist (weight loss) | Higher | 5 to 10 ng/mL | 6 months post-start | Reassess and reduce if above 60 ng/mL |